Comparing Novel Positron Emission Tomography Myocardial Perfusion Imaging with Conventional Single-Photon Emission Computed Tomography by Vlontzou, Evangelia
Comparing Novel Positron Emission 
Tomography Myocardial Perfusion 
Imaging with Conventional Single-Photon 
Emission Computed Tomography
Evangelia Vlontzou, MD
A B S T R A C T
For myocardial perfusion imaging, single-photon emission computed tomography 
(SPECT) technology is widely accepted by the cardiological community. It is sup-
ported by rich literature and has acceptable diagnostic accuracy. However, it does 
have limitations with false positive studies especially in women and obese patients and 
underestimates multivessel coronary artery disease. Positron emission tomography 
(PET) technology appears to be able to improve the diagnostic accuracy in detecting 
coronary artery disease. It offers qualitatively better images with shorter acquisition 
times and lower radiation burden on patients and personnel. It has the advantage of 
absolute quantification of myocardial blood flow for multivessel coronary disease di-
agnosis and is superior in the assessment of myocardial viability. In absolute terms it 
is an expensive method but avoiding the cost of additional diagnostic tests in equivocal 
studies makes it cost effective. Its availability is improving and it is expected to help in 
advancing nuclear cardiology.
I N T R O D U C T I O N
Radioisotope imaging of myocardial perfusion started in 1970 and peaked in the 
1990’s with advanced single-photon emission computed tomography (SPECT) systems 
and new radiopharmaceuticals. Almost in parallel, positron emission tomography 
(PET) technology became possible but only recently won support and is recognized 
for use in the imaging of myocardial perfusion.1-3 The main limitations delaying its 
timely use were the high cost of PET cameras hampering its availability, the cost and 
availability of radiopharmaceuticals for PET and the limited scientific literature.4,5 The 
increasing use of PET in clinical oncology over the last decade led to a reassessment of 
PET technology in clinical cardiology. The position of SPECT imaging of myocardial 
perfusion is widely accepted, evidenced by a wealth of literature, familiar to physicians, 
with clear guidelines for managing patients. Despite that, it has disadvantages that lead 
to inconclusive results and necessitate further patient examinations. The insufficiency 
of attenuation correction and tracer activity in the liver and intestine with technetium-
based radiopharmaceuticals, despite the experience of physicians, use of gated SPECT 
RevIew
Department of Nuclear Medicine, 
Evagelismos Hospital, Athens, Greece
HOSPITAL CHRONICLES 2012, 7(3): 149–155
Correspondence to:
Evangelia Vlontzou, MD,  
Department of Nuclear Medicine, 
Evagelismos Hospital,  
Athens, Greece;  
Tel: +30-213-2041437;  
E-mail: lilia_vlontzou@yahoo.gr
Manuscript received March 28, 2012; 
Revised manuscript received May 25, 
2012; Accepted June 1, 2012
Key wORDS: single-photon emission 
computed tomography; positron 
emission tomography; myocardial 
perfusion imaging; coronary artery 
disease; myocardial ischemia; 
myocardial viability
AbbreviAtions
ACC = American College of Cardiology
ASNC = American Society of Nuclear 
Cardiology 
CAD = coronary artery disease
CFR = coronary flow reserve
FDG = fluorodeoxyglucose 
LVEF = left ventricular ejection fraction
MBF = myocardial blood flow
PET = positron emission tomography
SPECT = single-photon emission 
computed tomography
Tl = thallium
Conflict of Interest: none declared
150
HOSPITAL CHRONICLES 7(3), 2012
and image acquisition in prone position, SPECT still leads to 
non-diagnostic tests particularly in obese patients and women. 
The inability to absolutely quantify myocardial blood flow 
(MBF) with SPECT underestimates the degree of ischemia 
and presence of multivessel coronary artery disease (CAD).6,7 
P e T  A N D  R A D I O P H A R M A C e U T I C A L S
A growing literature shows that PET can be an alternative 
solution to SPECT limitations. The radiopharmaceuticals and 
their characteristics8 for the two technologies are shown in Ta-
ble 1. The radiopharmaceuticals for PET have better extraction 
fraction than SPECT tracers and more linear uptake at higher 
flow rates. The short half time of PET radiopharmaceuticals 
results in short-time protocols. The rest/stress study with 82Rb 
can be completed in 20-30 minutes while the corresponding 
SPECT process requires more time from the patient as well 
as a busy laboratory,9,10 since it takes 3-5 hours. The available 
improvements in SPECT hardware and software offer faster 
acquisition with lower dosimetry and qualitatively better imag-
ing but they increase cost and are being introduced at a time 
of declining reimbursement and utilization.10 A limitation 
resulting from the short half-life of PET radiopharmaceuticals 
is the inability to perform regular stress test with only alterna-
tive the pharmaceutical stress. 
13N-NH3 offers high quality images and the capability of 
absolute quantitative assessment of MBF. However, it suffers 
from an availability standpoint. Its production requires on-site 
cyclotron which increases the cost.5,11 15O-H2O has the ability 
to diffuse freely across capillary and cell membranes and this 
makes the tracer almost ideal for quantitative assessment of 
myocardial blood flow. But the images are non-satisfactory 
and its use is restricted to sites with a cyclotron.8,10 82Rb can 
be produced from a 82Sr/82Rb generator and has better avail-
ability compared to the previous radiopharmaceuticals since 
the existence of the generator with proper patient handling 
makes it cost effective. 82Rb is analogous to potassium and 
the 78 seconds of its half-life (t1/2) reduce the time between 
examinations and allow their repetition after 15 min if technical 
problems arise. However, the relative rather than the absolute 
myocardial flow is estimated and for this reason it does not 
solve the SPECT problem of low sensitivity in patients with 
diffuse microvascular or balanced disease.12 Programs for 
absolute blood flow measurements with 82Rb exist but this is 
not in wide use.
New radiopharmaceuticals like fluridipaz-F18 based on 
18F labeling are being developed and evaluated in order to 
overcome the existing limitations. These do not require on-site 
cyclotron, are produced with the technology and availability 
of radiopharmaceuticals for oncologic patients, have longer 
half life and allow stress tests and possibly have lower cost 
since they allow single patient doses.13,14 In general, the PET 
radiopharmaceuticals have higher cost and limited availability 
with 82Rb being the most commonly used. Because of the short 
half life, higher doses can be administered resulting in shorter 
duration studies.
R A D I A T I O N
It has been estimated that in the US population, 20% of the 
yearly collective radiation dose received is from radioisotope 
studies of myocardial perfusion and in a recent publication 
it was estimated that 7400 more cancers may occur based on 
myocardial perfusion testing frequencies in the US in 2008.15 
However, the relationship between this level of radiation 
exposure and cancer risk is disputed and physicians should 
follow the relevant recommendations in order to achieve the 
desired result with minimum risk.
The radiation burden for patients is lower with PET radi-
opharmaceuticals compared to SPECT because of the short 
half life despite the larger administered doses (Table 2).16 For 
the laboratory personnel, despite PET radiopharmaceuticals 
TABLe 1. Radiopharmaceuticals and Their Characteristics for the Two Technologies of PET and SPECT
Agent Half-life Production extraction Myocardial Uptake-Mechanism
PeT
82Rb 78 sec Generator 50-60% Na/K-ATPase (perfusion)
13N-NH3 10min Cyclotron 80% Diffusion/metabolic trapping (perfusion)
15O- H2O 2min Cyclotron Diffusible Free diffusion
18F-FDG 110min Cyclotron 1-3% Glucose transport/hexokinase (viability) 
SPeCT
201Tl 73h Cyclotron 73% Potassium analog
99mTc-Sestamibi/Tetrafosmin 6h Generator 50-60% Mitochondrial uptake
FDG = fluorodeoxyglucose; PET = positron emission tomography; SPECT = single photon emission computed tomography.
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having high energy photons that could theoretically represent 
greater radiation burden, this is not confirmed because of dif-
ferences in radiotracer administration, in various acquisition 
and stress-testing tasks.17 
I M A G e  R e S O L U T I O N
Imaging with PET provides higher spatial and temporal 
resolution compared to SPECT, and robust and common use 
of attenuation correction.18 The higher temporal resolution 
permits dynamic imaging and the higher spatial resolution 
and the attenuation correction offers better sensitivity and 
specificity for CAD detection than SPECT. The correction of 
attenuation with PET is more accurate than in SPECT because 
of the uniform attenuation of high energy photons (511 vs 140 
KeV for 99mTc). As a result of attenuation correction we have 
better image quality, especially in sub-populations like women 
where breast attenuation is frequent and in obese patients and 
the direct result compared to SPECT is an increase in specific-
ity and normalcy rate leading to fewer inconclusive studies.14 
yoshinaga et al19 showed that in patients with equivocal 
SPECT, the quality of scans was rated as good in only 20% of 
SPECT vs 90% of PET. Bateman et al reached similar conclu-
sions in matched patients.20 The attenuation artifacts of PET 
are a lot fewer because of the higher imaging activity of the 
radiopharmaceutical tracer and the attenuation correction. 
The artifacts because of liver and intestine activity are more 
in SPECT studies than PET (41% vs 5%) and consequently 
the reader certainty was greater with PET than SPECT (96% 
vs 82%) independent of gender or body mass index, with 4% 
equivocal studies with PET and 18% with SPECT. Examples 
of PET myocardial perfusion images are displayed in Fig. 1-3. 
D I A G N O S T I C  C A P A B I L I T y
The diagnostic accuracy of PET for CAD diagnosis has 
been verified in many studies. In Di Carli’s meta-analysis,21 
90% sensitivity and 89% specificity is reported from 9 studies, 
most with use of 82Rb-PET. In direct comparison with 201Tl-
SPECT and 82Rb or 13N-NH3-PET in three studies, sensitivity 
was 91% for PET and 81% for SPECT, while specificity was 
93% vs 85% in CAD diagnosis.8 Even with technetium-based 
radiopharmaceuticals and gated acquisition, specificity was 
93% for PET vs 73% for SPECT in Bateman’s study and 
especially in the female population 86% vs 64%.20 Using as 
a threshold luminal stenosis of 70%, the overall diagnostic 
accuracy for PET was 89% vs 79% for SPECT and this was 
due to the improved specificity of PET, while sensitivity was 
marginally greater at 87% vs 82%. 
In the same study, recognized as the most notable, it was 
shown that PET was better than SPECT (71% vs 48%) in the 
diagnosis of multivessel CAD, probably related to differences 
in tracer kinetics between 82Rb and 99mTc-sestamibi. The extrac-
tion fraction of radiopharmaceuticals for SPECT is limited to 
higher flow rates resulting in limited usefulness in patients with 
incipient coronary artery disease.6,7
82Rb has relative higher extraction of the 99mTc-sestamibi 
at high flow rates and this could explain in part the improved 
ability of PET to recognize better multivessel CAD.3 However, 
PET, at a 30% rate, misclassifies patients with multivessel dis-
ease as having one vessel disease or even misses some patients 
with balanced ischemia.3
One additional PET advantage is the capability of assess-
ment of left ventricular ejection fraction (LVEF) at the peak 
of pharmaceutical stress and of course the change from rest, 
offering prognostic information which is additive to that de-
termined by the extent and severity of perfusion abnormality 
alone.22 Peak -stress myocardial function cannot be assessed 
with typical SPECT protocols. In Dorbala’s study,23 it is stated 
that by assessing the LVEF change, the diagnostic sensitivity 
for multivessel disease increases from 50% to 79%.
In general, PET appears more important because the 
number of false positive studies is reduced and offers high 
specificity compared to SPECT. The higher sensitivity of 
PET can be explained by the better spatial resolution and 
the better tracer extraction. Regarding the prognostic value 
for SPECT, there are a lot of data, while for PET only a few 
studies exist,24-26 therefore the prognostic value of PET is not 
as well documented as SPECT.
M y O C A R D I A L  B L O O D  F L O w
The capability of absolute quantification of myocardial 
blood flow (MBF) at rest and during stress and coronary flow 
TABLe 2. Patient Radiation Exposure by the Most Fre-
quent Diagnostic Nuclear Imaging Procedures16
Study
Total Body effective 
Dose (mSv)
201Tl stress and re-injection (110+37 MBq) 25.1
99mTc-sestamibi 1 day (370+1,100 MBq) 10.7
99mTc-sestamibi 2 days (1100+1,100 MBq) 16.0
201Tl/
99mTcDual isotope (110+1,100 MBq) 27.3
82Rb stress-rest PET (1100+1,100 MBq) 7.5
13NH3 stress-rest PET (500+500 MBq) 2.0
H215O stress-rest PET (900+900 MBq) 1.7
18F-FDG PET viability (259 MBq) 4.9
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FIGURe 1. Myocardial perfusion PET 
images using 82Rb in a patient with severe 
angina. PET shows reversibility in the in-
ferior wall region.
FIGURe 2. Myocardial perfusion PET images using 82Rb in a 
patient with four months history of angina and positive stress 
test at low work load. Moderate to severe anteroapical and sep-
tal inducible ischemia (LAD territory). LAD = left anterior de-
scending (coronary artery).
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reserve (CFR) by dynamic PET is an important PET advan-
tage. The high temporal resolution of PET enables dynamic 
imaging providing robust and reproducible time activity data 
needed to quantify regional and global MBF in milliliters 
per minute per gram of tissue, thus PET is able to quantify 
absolute MBF and coronary flow reserve.27 13N-NH3 and 15O-
H2O have been used for these measurements and constitute 
a non invasive gold standard for the assessment of MBF and 
CFR.28,29 82Rb has also been used but with limitations because 
it requires a correction for its lower extraction fraction.6 Sev-
eral methods have been used with 82Rb to achieve sufficient 
accuracy for the evaluation of CFR and in quantification of 
MBF and it is expected that they will help in implementing 
flow quantification into clinical PET practice because 82Rb 
is the most frequently used radiopharmaceutical. However, 
it is accepted that the involvement of microcirculation plays 
a critical role in pathogenesis of many cardiac disorders and 
the quantitative flow measurement is useful in cases like wide-
spread CAD with balanced ischemia, evaluation of collateral 
flow and identification of endothelial dysfunction in preclini-
cal disease. Also CFR measurements with PET can provide 
prognostic information. Patients with normal perfusion but 
pathological CFR <2 were independently associated with 
higher annual event rate (1.4% vs 6.3%) and cardiac death 
rate (0.5% vs 3.1%) in the study of Herzog et al.30 The clinical 
value of flow quantification with PET is a promising method 
for patient risk stratification and an object of many studies 
because there is no credible technique in SPECT. 
C O M P L e M e N T A R y  I N F O R M A T I O N
The recent wide use of PET/computed tomography (CT) 
imaging systems offers complementary morphological and 
functional information like calcium scoring, increasing the 
prognostic value of the method and the negative prognostic 
value, especially in patients with low CAD prevalence.31 Re-
cently, special pinhole collimators and arch arrangements of 
SPECT detectors have increased the SPECT count sensitivity 
but cost is also significantly increased and current availability 
is limited.32 Despite that, the count sensitivity of PET remains 
greater and its high quality images lead to high interpretive 
certainty and greater diagnostic accuracy.
M y O C A R D I A L  v I A B I L I T y
Positron emission tomography with18F-FDG is considered 
FIGURe 3. Myocardial perfusion PET 
images using 82Rb in a patient with pre-
vious myocardial infarction shows stable 
defect in anteroseptal and apical region.
154
HOSPITAL CHRONICLES 7(3), 2012
by many the gold standard for the assessment of myocardial 
viability, based on the notion that the assessment of only 
the myocardial perfusion is not enough to predict function 
recovery after revascularization. 18F-FDG is the best known 
radiopharmaceutical for oncology but also for the assessment 
of myocardial viability. 18F-FDG uptake has been observed in 
areas of markedly reduced or absent radiopharmaceutical up-
take in SPECT. Tillisch et al33 compared the 18F-FDG uptake in 
patients with advanced CAD and affected regional and global 
function before and after revascularization and showed that 
imaging of viable myocardium was superior with 18F-FDG-PET 
compared to SPECT, in patients benefiting from revasculariza-
tion. Approximately 30-50% of scarred tissue areas with 201Tl 
showed FDG uptake and were characterized as viable. Later 
in 2007, Schinkel et al34 in a comprehensive and systematic 
review, showed higher sensitivity of 18F-FDG-PET (92%) 
compared to 201Tl and technetium based radiopharmaceuti-
cals, including magnetic resonance imaging and dobutamine 
echocardiography. The specificity was highest for dobutamine 
echocardiography and the highest negative prognostic value 
was with 18F-FDG-PET. With 201Tl reinjection the viability as-
sessment was comparable to FDG but the weight of evidence 
favors the use of FDG.35 Recent data from the Ottawa-Five 
substudy of PARR236 show that when 18F-FDG-PET is avail-
able and is used by experienced personnel it has the advantage 
in assessing patients who will benefit from revascularization. 
18F-FDG-PET accurately predicts the improvement of global 
LVEF and of regional wall motion after revascularization, 
especially when blood flow is reduced by >50% and there 
is relatively high glucose uptake. Even in perfusion imaging 
with 82Rb, 18F-FDG-PET often shows additional viable tissue 
in patients with fixed 82Rb perfusion defects or in patients with 
only partial stress-inducible reversibility.8
R e C O M M e N D A T I O N S
An advantage of SPECT over PET is that its wide use for 
many years has validated its prognostic and diagnostic value 
in many patient groups. The increasing use of PET leads to 
the need to select patients who will benefit from it. There 
are no guidelines as to which patients should be subjected 
to PET or SPECT, although the reasons for performing a 
PET study should follow previously published ACC/ASNC 
guidelines and appropriateness criteria for nuclear cardiac 
imaging. However, a recent ASNC statement recommended 
that PET be considered as the first line option for patients 
referred for myocardial perfusion test when a nuclear perfu-
sion test is indicated.37 Patients that would benefit from PET 
until now are those with equivocal SPECT, obese patients and 
women because of attenuation correction, patients that cannot 
undergo stress test and are subject to pharmaceutical stress 
because of higher diagnostic accuracy in PET and patients 
with highly suspected CAD and normal SPECT study, as well 
as patients with highly suspected multivessel CAD or diffuse 
microvascular disease because of the quantification of absolute 
myocardial flow. However, claustrophobic or excessively obese 
patients are not suitable for PET, especially in hybrid PET/CT 
systems. In patients who can exercise, the exercise stress test 
adds important information to that of the images in SPECT. 
Finally, PET imaging in patients with advanced ischemic 
heart disease and left ventricular dysfunction historically 
have been the driving force for viability assessment because 
of PET’s accuracy in predicting the functional recuperation 
after revascularization.1,2 
C O N C L U S I O N S
Positron emission tomography (PET) perfusion imaging 
offers better images with higher resolution and better attenua-
tion correction than SPECT perfusion imaging. PET protocols 
are shorter and the patients are exposed to less radiation. All 
these lead to enhanced diagnostic certainty and accuracy and 
PET will enable nuclear cardiology to survive for years to come. 
However, at this time, SPECT myocardial perfusion imaging 
continues to be the main method, because this technique has 
been standardized for the protocols employed and has been 
tested in all patient populations.
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